Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Syed Haider

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer GrowthAnthony Cheung, Alicia M Chenoweth, Annelie Johansson, et al.
Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.
Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.
Journal of the National Cancer Institute|June 30, 2014
Therapeutic targeting of integrin αvβ6 in breast cancerKate M Moore, Gareth J Thomas, Stephen W Duffy, et al.
The Lancet. Neurology|October 18, 2024
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trialKeith W Muir, Gary A Ford, Ian Ford, et al.
Nature Communications|November 14, 2018
Pathway-based subnetworks enable cross-disease biomarker discoverySyed Haider, Cindy Q Yao, Vicky S Sabine, et al.
European Urology|November 6, 2016
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate TumorsEmilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, et al.
Ebiomedicine|May 7, 2018
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate CancerLingjian Yang, Darren Roberts, Mandeep Takhar, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer GrowthAnthony Cheung, Alicia M Chenoweth, Annelie Johansson, et al.
Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.
Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.
Journal of the National Cancer Institute|June 30, 2014
Therapeutic targeting of integrin αvβ6 in breast cancerKate M Moore, Gareth J Thomas, Stephen W Duffy, et al.
The Lancet. Neurology|October 18, 2024
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trialKeith W Muir, Gary A Ford, Ian Ford, et al.
Nature Communications|November 14, 2018
Pathway-based subnetworks enable cross-disease biomarker discoverySyed Haider, Cindy Q Yao, Vicky S Sabine, et al.
European Urology|November 6, 2016
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate TumorsEmilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, et al.
Ebiomedicine|May 7, 2018
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate CancerLingjian Yang, Darren Roberts, Mandeep Takhar, et al.
Pageof 21